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14-3-3Selenoprotein W (SelW) is expressed in various tissues, particularly in skeletal muscle. We have previously
reported that SelW is up-regulated during C2C12 skeletal muscle differentiation and inhibits binding of 14-3-3
to its target proteins. 14-3-3 reduces myogenic differentiation by inhibiting nuclear translocation of transcrip-
tional co-activator with PDZ-binding motif (TAZ). Phosphorylation of TAZ at Ser89 is required for binding to
14-3-3, leading to cytoplasmic retention of TAZ and a delay in myogenic differentiation. Here, we show that
myogenic differentiation was delayed in SelW-knockdown C2C12 cells. Down-regulation of SelW also increased
TAZ binding to 14-3-3, which eventually resulted in decreasing translocation of TAZ to the nucleus. However,
phosphorylation of TAZ at Ser89 was not affected. Although phosphorylation of TAZ at Ser89 was sustained by
the phosphatase inhibitor okadaic acid, nuclear translocation of TAZ was increased by ectopic expression of
SelW. This result was due to decreased binding of TAZ to 14-3-3. We also found that the interaction between
TAZ andMyoDwas increased by ectopic expression of SelW. Taken together, theseﬁndings strongly demonstrate
that SelW enhances C2C12 cell differentiation by inhibiting TAZ binding to 14-3-3.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Selenoprotein W (SelW) is the smallest selenoprotein (10 kDa)
containing a selenocysteine (Sec, U) in a conserved – CXXU – motif,
which corresponds to the – CXXC – redox motif of thioredoxin [1,2].
SelWmayhave anti-oxidant activity [3–5]. SelW is localized in the cytosol
and is expressed in various tissues; however, it is particularly abundant in
the skeletal muscle and brain of mammals [6–9]. SelW deﬁciency causes
Keshan disease andwhite muscle disease inmammals [4,10,11]. We pre-
viously reported that SelWmRNA and protein expression is up-regulated
during mouse skeletal muscle C2C12 cell differentiation by a MyoD-
dependent increase in its promoter activity [12]. However, the precise
function of SelW has not been determined during skeletal muscle
C2C12 cell differentiation. We previously reported that SelW plays key
roles in cell cycle progression by interacting with 14-3-3 [13]. SelW
interacts with 14-3-3 to repress its interaction with target proteins
including CDC25B and Rictor [13,14]. SelW has been identiﬁed as a 14-
3-3 binding protein in a nuclear magnetic resonance (NMR) study
[15,16].DZ-bindingmotif; NMR, nuclear
y chain; MCK, muscle creatine
hatase 1; Sec, U, selenocysteine
ical Genetics Branch, National
ealth, Bethesda, MD 20892, USA.14-3-3 is a family of regulatorymolecules that plays important roles
in functionally diverse signaling processes such as bacterial pathogene-
sis, neuronal development, and cell growth control through its interac-
tions with various binding partners [17,18]. 14-3-3 is present in the
brain, heart, liver, and testes [19,20]. It is clear that the function of
many cellular proteins is modulated by binding to 14-3-3 [17]. 14-3-3
binds to phosphorylated protein ligands to regulate cell growth, cell
cycle progression, and apoptosis [21–24]. 14-3-3 is also a regulator of
cell differentiation by interacting with the transcriptional co-activator
with PDZ-binding motif (TAZ) [25,26], and the transcriptional activity
of TAZ is negatively regulated by its interaction with 14-3-3 [27–29].
Binding of TAZ to 14-3-3 reduces the transcriptional activity of TAZ for
inducing target gene expression including myogenin, myosin heavy
chain (MyHC) and muscle creatine kinase (MCK) [26].
TAZ was ﬁrst identiﬁed as a 14-3-3 binding protein [30] involved in
the muscle development [31]. Translocation of TAZ to the nucleus is
required for its interaction with several transcription factors including
MyoD, a key regulatory factor in skeletal muscle differentiation [26].
Transcriptional activity and nuclear translocation of TAZ is regulated
by the Hippo signal pathway [28–30]. The Hippo pathway plays a key
role in the control of organ size, cell proliferation, and differentiation.
The signaling components large tumor suppressor (LATS) and protein
phosphatase 1 (PP1) regulate nuclear translocation, transcriptional
activity, and stability of TAZ [28,29]. Transcriptional activity and nuclear
translocation of TAZ is inhibited by LATS. LATS phosphorylates TAZ on
several serine residues including Ser89 [27]. Phosphorylation of TAZ at
Ser89 by LATS leads to its cytoplasmic retention and transcriptional
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TAZ, in which the Ser is replaced with Ala (S89A mutant), disrupts the
interaction with 14-3-3, leading to increased translocation of TAZ to
the nucleus [25,27,30]. PP1 is a serine/threonine phosphatase involved
in various cellular processes [32]. PP1 de-phosphorylates TAZ at Ser89.
De-phosphorylation of TAZ at Ser89 by PP1 promotes translocation
of TAZ to the nucleus, leading to its transcriptional activity [29,33].
Additionally, ectopic expression of PP1 attenuates the interaction be-
tween TAZ and 14-3-3 and increases translocation of TAZ to the nucleus
through de-phosphorylation of TAZ at Ser89 [33]. However, the molecu-
lar mechanism regulating TAZ remains unknown. Because TAZ nuclear
translocation and transcriptional activity are negatively regulated by
the interaction with 14-3-3, which also interacts with SelW, we sought
to determine the function of the complex between SelW and 14-3-3
for regulating TAZ nuclear translocation during skeletal muscle C2C12
cell differentiation. In this study, we have shown that the complex
formation between SelW and 14-3-3 was increased during C2C12 cell
differentiation compared to that during cell proliferation, whereas bind-
ing of TAZ to 14-3-3was decreased during C2C12 cell differentiation.We
also found that down-regulation of SelW reduced C2C12 cell differentia-
tion due to increased interaction between TAZ and 14-3-3, which
decreased translocation of TAZ to the nucleus, whereas nuclear translo-
cation of TAZwas increased by ectopic expression of SelW, which result-
ed from inhibiting TAZ binding to 14-3-3. However, TAZphosphorylation
at Ser89 was not affected by either over-expression or down-regulation
of SelW. Although phosphorylation of TAZ at Ser89 was retained by
okadaic acid (OA), binding of TAZ to 14-3-3 was inhibited by ectopic
expression of SelW. Additionally, ectopic expression of SelW increased
binding of TAZ to MyoD. Taken together, these results suggested that
SelW elevated skeletal muscle C2C12 cell differentiation by interrupting
the interaction between TAZ and 14-3-3.
2. Materials and methods
2.1. Cell culture and transfection
Mouse skeletal muscle C2C12 (CRL-1722) myoblast cells were pur-
chased from the American Type Culture Collection (Manassas, VA, USA)
and were propagated in growth medium (GM) consisting of Dulbecco's
Modiﬁed Eagle Medium (DMEM; Gibco, Grand Island, NY, USA) contain-
ing 10% fetal bovine serum (FBS; Gibco) at 37 °C in 5% CO2. To induce
differentiation, the cells were cultured to ~100% conﬂuence in GM
followed by an exchange to differentiation medium (DM) consisting of
DMEM containing 2% heat-inactivated horse serum. The DM was
exchanged every day. Human embryonic kidney 293 (HEK293) cells
were grown in DMEM containing 10% FBS at 37 °C in 5% CO2. The cells
were seeded at a density of 3 × 105 cells in 60-mm dishes for transient
transfection. Twelve hours after seeding, the cells were transfected
using the Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer's instructions [12].
2.2. RNA interference and plasmids
The siSelW used in this study was designed by Invitrogen. The
sequence for mouse siSelW was as follows: siSelW 5′-CCG GAA ACU
GGU GAC CGC CAU CAA A-3′. A point mutation in SelW at Ser13 to Cys
was generated by site-directed mutagenesis of the cDNA by polymerase
chain reaction (PCR) using the pcDNA 3.1+/SelW plasmid [12,13]. The
HA-14-3-3β and Flag-TAZ plasmids were kindly provided [25].
2.3. Antibodies and western blotting
The cells werewashed twicewith PBS and lysedwith lysis buffer con-
taining 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 0.1%
SDS, 1 mM EDTA, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF), 5 μg/ml
aprotinin, 5 μg/ml leupeptin, 3 mM dithiothreitol (DTT), phosphataseinhibitor 1mMNaF, and 1mMNa3VO4. The proteins fromwhole-cell ly-
sates were separated by 6–15% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and the separated proteins were trans-
ferred to a membrane that was blocked with 5% skim milk for 1 h and
probed with speciﬁc antibodies. The antibodies were obtained from the
following sources: anti-TAZ and anti-phospho-TAZ (Ser89) were kindly
provided by Prof. J. H. Hong (Korea University); anti-MyoD was from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) or from Pharmingen
(BD Bioscience, San Jose, CA, USA); anti-myogenin was from Pharmingen
(BD Bioscience); anti-MyHC and anti-Flag were from Sigma (Sigma-
Aldrich, St. Louis, MO, USA); anti-His and anti-HA were from ABM
(Richmond, BC, Canada); and anti-α-tubulin was obtained from AB
Frontier (Daejeon, Republic of Korea). The cell lysates were incubated
with LDS sample buffer and reducing reagent (Invitrogen) at 70 °C for
10 min to detect SelW. The lysates were then separated on a 12% Bis-
Tris gel (Invitrogen), transferred to a membrane, and probed with the
SelW antibody. HRP-conjugated secondary antibodies were incubated
with the membranes for 1 h [13].2.4. Quantitative PCR
Total RNA was isolated from C2C12 cells using TRIzol reagent
(Invitrogen). The cDNA was ampliﬁed with LightCycler 480 SYBR
Green I Master (Roche Diagnostics, Manheim, Germany). The primers
for the gene sequenceswere designedbetweendifferent exons to prevent
DNA ampliﬁcation. The following forward and reverse primers were
used: for SelW, 5′-GTG TAT TGT GGA GCT TGA GGC-3′ and 5′-CCA AGG
CAG CTT TGA TGG CGG-3′; GAPDH, 5′-AGG TCG GAG TCA ACG GAT
TT-3′ and 5′-AGG TGG AGG AGT GGG TGT CG-3′.2.5. Immunoprecipitation
Cellswere lysedwith immunoprecipitation buffer containing50mM
Tris–HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
5 mM EDTA, 1 mM PMSF, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 20 mM
NaF, and 2 mM Na3VO4. The lysates were mixed with antibodies
overnight, and the immune complexeswere then incubatedwith Protein
A or G beads for 1.5 h. The beads were washed and boiled 2× with SDS
sample buffer for 3 min. The samples were loaded onto SDS-PAGE gels,
transferred to a membrane, and incubated with primary antibody at
4 °C for overnight. After a further incubation with HRP-conjugated
secondary antibody for 1 h at room temperature, immunoreactive
bands were visualized using a West Pico Enhanced ECL Detection kit
(Pierce, Rockford, IL, USA) [34].2.6. Nuclear fraction
C2C12 cellswerewashedwith cold PBS twice andwere harvested by
scrapping and centrifugation at 850 ×g for 5 min at 4 °C. After the
supernatant was removed, the cells were resuspended in lysis buffer
containing 10 mM HEPES pH 7.9, 10 mM KCL, 0.1 mM EDTA, 1 mM
DTT, 0.5 mM PMSF, 5 μg/ml leupeptin, and 5 μg/ml aprotinin. After
gentle vortexing, the cells were incubated on ice for 15 min, and then
10% NP-40 was added to the samples at a ﬁnal concentration of 0.5%.
After thoroughly vortexing the samples for 10 sec, the lysates
were centrifuged at 16,000 ×g for 2 min at 4 °C. The supernatants
were collected as the cytosolic extract, and the pellets were
washed twice with lysis buffer. The pellets were resuspended in
nuclear extraction buffer containing 20 mM HEPES pH 7.9, 0.4 M
NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 5 μg/ml leupeptin, and
5 μg/ml aprotinin and vortexed strongly for 10 min at 4 °C. After
centrifugation at 16,000 ×g for 30 min at 4 °C, the soup was collected
as the nuclear extract [13].
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Cells on coverslipswerewashedwith cold PBS,ﬁxedwith 3.7% form-
aldehyde for 15min at room temperature (RT), permeabilizedwith 0.1%
Triton X-100 for 5 min, and incubated with 2% BSA overnight to block
nonspeciﬁc staining. The cells were then immunostained with antibod-
ies in 0.1% BSA for 1 h at RT, washed three times with PBS, and further
incubated with ﬂuorescence conjugated secondary antibodies (FITC)
for 1.5 h at RT. The cells were stained with DAPI for 3 min to visualize
nuclei. Finally, the cells were mounted on slides using mounting
solution. Immunoﬂuorescence was examined using a ﬂuorescence
microscope (Zeiss LSM 510 META; Oberkochen, Germany).Fig. 1. SelW is up-regulated during C2C12 cell differentiation. (A) Expression of muscle-speciﬁc
The cells were harvested at the indicated time points, andwere then analyzed bywestern blot u
was carried outwith SelW speciﬁc primers. Error bars represent± standarddeviation (s.d.). (C)
at D1 after transfection with siSelW. SelW protein was analyzed by western blot. α-Tubulin se
siSelW. The cells were harvested at the indicated time points after transfection and were analyz
(left). The quantity of MyoD, myogenin and MyHC expression represents the average values a
Error bars represent ± standard deviation (s.d.), and the p value compares the siControl to si
differentiation. Microscopic observations were conducted at the indicated time points. Scale ba3. Results
3.1. SelW is involved in C2C12 cell differentiation
The myogenic differentiation program can be triggered in C2C12
myoblasts by shifting conﬂuent C2C12 cells from GM to DM. To induce
differentiation, C2C12 myoblasts were maintained in GM up to ~100%
conﬂuence (D0). After exchanging themediumwithDM, differentiating
C2C12 cells were observed at 1, 3, and 5 days of differentiation (D1, D3
and D5, respectively) [12]. Protein expression of well-known muscle-
speciﬁc markers such as MyoD, myogenin, and MyHC was conﬁrmed
during C2C12 cell differentiation. Expression of MyoD, myogenin, andmarker proteins during C2C12 cell differentiation. C2C12 cell differentiation was induced.
sing the indicated antibodies.α-Tubulin served as the loading control. (B) Quantitative PCR
C2C12 cellswere transiently transfectedwith siControl or siSelW. The cellswere harvested
rved as the loading control. (D) C2C12 cells were transiently transfected with siControl or
ed bywestern blot using the indicated antibodies.α-Tubulin served as the loading control
t D3. The graph indicates the results from three independent experiments (***p b 0.001).
SelW (right). (E) SelW-knockdown C2C12 cells were established and used for myogenic
r: 20 μm.
Fig. 2. Inhibition of 14-3-3 binding to TAZ is required for TAZ nuclear translocation.
(A) Nuclear translocation of TAZ during C2C12 cell differentiation. The cytoplasmic and nu-
clear fractionswereobtained at the indicated timepoints. Sampleswereprobed forα-tubulin
as a cytoplasmic marker and lamin B1 as a nuclear marker. (B) C2C12 cells were co-
transfected with Flag-TAZ or HA-14-3-3β, and the cells were harvested 24 h after transfec-
tion. Cell extracts were immunoprecipitated with anti-Flag or anti-Mouse IgG antibodies
and were immunoblotted with anti-HA antibody. (C) C2C12 cells were co-transfected with
Flag-TAZ or HA-14-3-3β and the cells were harvested at the indicated time points. Cell
extracts were immunoprecipitated with anti-Flag and were immunoblotted with anti-HA
antibody. (D) C2C12 cells were transfected with HA-14-3-3β. After transfection, the cells
were cultured in GM or DM. The cells were stained with anti-TAZ antibody and anti-HA
antibody and then incubated with secondary IgG linked with Alexa Fluor 488 (green, TAZ)
or Alexa Fluor 594 (red, HA-14-3-3β). DNA was stained with DAPI (blue). Images of the
samples were obtained using a confocal microscope. Scale bar: 10 μm.
1359Y.H. Jeon et al. / Biochimica et Biophysica Acta 1843 (2014) 1356–1364MyHCwas increased during C2C12 cell differentiation. Phospho-histone
H3, a cell proliferation marker, was only detected in C2C12 myoblasts
cultured in GM (Fig. 1A). As shown in a previous report [12], we
reconﬁrmed that the expression of SelW mRNA was up-regulated
during C2C12 cell differentiation,whichwas determined by quantitative
PCR (Fig. 1B). Because SelW mRNA expression was increased during
C2C12 cell differentiation, we next investigated whether down-
regulation of SelW might inhibit C2C12 cell differentiation. Thus, we
examined MyoD, myogenin, and MyHC expression levels during myo-
genic differentiation in SelW-knockdownC2C12 cells.Wepreferentially
observed that SelW expressionwas efﬁciently reduced by SelW-speciﬁc
siRNA (Fig. 1C). The expression levels of the muscle-speciﬁc gene
markers myogenin and MyHC was decreased during C2C12 cell differ-
entiation of SelW-knockdown cells compared to that in control cells,
whereas MyoD expression remained unchanged (Fig. 1D). We also
found that the level of myotube formation was reduced in SelW-
knockdown C2C12 cells, compared to control cells (Fig. 1E). These
results indicate that SelW is involved in C2C12 cell differentiation.
3.2. TAZ binding to 14-3-3 is diminished during myogenic differentiation
TAZ translocation to the nucleus is required to elevate the expression
of genes such as myogenin, MyHC, and MCK and stimulate myogenic
differentiation [26]. We found that translocation of TAZ to the nucleus
was increased during C2C12 cell differentiation (Fig. 2A). Cytoplasmic
retention and transcriptional inactivation of TAZ is caused by its interac-
tion with 14-3-3 [30]. To investigate the interaction between TAZ
and 14-3-3 during C2C12 cell differentiation, we overexpressed Flag-
tagged TAZ and HA-tagged 14-3-3 for an in vitro interaction study. We
observed binding of TAZ to 14-3-3 (Fig. 2B), which decreased during
C2C12 cell differentiation (Fig. 2C). An immunoﬂuorescence confocal
microscopic analysis revealed that TAZ was translocated to the nucleus
under differentiating conditions (Fig. 2D). These results indicate that
inhibiting the interaction between TAZ and 14-3-3 is required for
nuclear translocation of TAZ.
3.3. Binding of SelW to 14-3-3 affects nuclear translocation of TAZ
Wenext investigatedwhether SelWwas involved in translocation of
TAZ to the nucleus for myogenic differentiation. We found that down-
regulation of SelW resulted in a decrease in TAZ translocation to the
nucleus during C2C12 differentiation compared to that of control cells
(Fig. 3A). To understand the interaction studies of SelW in skeletalmus-
cle differentiation,we expressed amutant SelWwhere Secwas changed
to Cys (U13C). Expression of recombinant wild type SelW was very
difﬁcult to work with, as the codon for Sec, UGA, was often recognized
as a stop codon. Thus, we used a mutant SelW, in which the Sec was
replaced with a Cys (U13C). Although SelW modulated translocation
of TAZ to thenucleus, it did not interactwith TAZ (Fig. 3B). To investigate
how nuclear translocation of TAZ was decreased by down-regulating
SelW, we analyzed the TAZ translocation regulatory pathway from the
cytoplasm to the nucleus. It has been reported that translocation of
TAZ to the nucleus is regulated by complex formation between TAZ
and 14-3-3 [30]. We have previously reported that SelW interrupts the
interaction between 14-3-3 and its target proteins [13,14]. Therefore,
we investigated whether SelW regulated translocation of TAZ from the
cytoplasm to the nucleus by interrupting its interaction with 14-3-3.
We found that binding of TAZ to 14-3-3 was signiﬁcantly increased in
SelW-knockdown C2C12 cells compared to that in control cells but did
not affect phosphorylation of TAZ at Ser89 (Fig. 3C). As expected, bind-
ing of SelW to 14-3-3 was increased during C2C12 cell differentiation
(Fig. 3D). We then investigated subcellular location of TAZ and 14-3-3.
Confocal microscopic observations revealed that almost all of the TAZ
was translocated to the nucleus compared to that in SelW-knockdown
cells, which was conﬁrmed by immunoﬂuorescence staining (Fig. 3E
Fig. 3. Binding of SelW to 14-3-3 is required for nuclear translocation of TAZ. (A) C2C12 cells were transiently transfectedwith siControl or siSelW. Cytoplasmic and nuclear fractionswere
obtained at the indicated time points after transfection and immunoblotted using the TAZ antibody. Sampleswere probed forα-tubulin as a cytoplasmicmarker and lamin B1 as a nuclear
marker (top). The quantity of nuclear TAZ represents the average values at the indicated time points. The graph indicates the results from three independent experiments (***p b 0.001).
Error bars represent ± standard deviation (s.d.), and the p value compares the siControl to siSelW (bottom). (B) C2C12 cells were co-transfected with Flag-TAZ or His-SelW(U13C), and
the cells were harvested 24 h after transfection. The cell extracts were immunoprecipitatedwith anti-Flag andwere then immunoblottedwith anti-His antibody. (C) C2C12 cells were co-
transfected with siSelW, Flag-TAZ, or HA-14-3-3β. The cells were harvested 24 h after transfection, immunoprecipitated with anti-Flag antibody, and then immunoblotted using the
indicated antibodies. (D) C2C12 cells were co-transfected with His-SelW(U13C) and HA-14-3-3β. The cells were harvested at the indicated time points, immunoprecipitated with anti-His
or anti-Mouse IgG antibodies, and were then immunoblotted using the indicated antibodies. (E) C2C12 cells were co-transfected with siControl or siSelW and HA-14-3-3β. The cells were
cultured for D1. The cells were stained with anti-TAZ and anti-HA antibodies and then incubated with secondary IgG linked with Alexa Fluor 488 (green, TAZ) or Alexa Fluor 594 (red, HA-
14-3-3β). DNA was stained with DAPI (blue). Images of the samples were obtained using a confocal microscope. Scale bar: 10 μm. (F) Nuclear translocation of TAZ proteins in (E) was
quantitatively analyzed according to whether it was higher in the nucleus (N N C), higher in the cytoplasm (N b C) or evenly distributed between the nucleus and cytoplasm (N= C).
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translocation of TAZ to the nucleus.
3.4. SelW promotes nuclear translocation of TAZ
We investigatedwhether ectopic expression of SelW(U13C) inhibited
binding of TAZ to 14-3-3 and promoted nuclear translocation of TAZ to
stimulate myogenic differentiation. Thus, we examined TAZ binding to
14-3-3 with or without SelW(U13C) co-expression. We observed thatectopic expression of SelW(U13C) decreased binding of TAZ to 14-3-3
compared to that in control cells but did not affect phosphorylation of
TAZ at Ser89 (Fig. 4A). Furthermore, translocation of TAZ to the nucleus
was increased by ectopically expressing SelW(U13C) (Fig. 4B). When
the cells were treated with OA, which is an inhibitor of PP1 and PP2A
[33,35], phosphorylation of TAZ at Ser89 was signiﬁcantly increased
with increasing amounts of OA (Fig. 4C), and TAZ binding to 14-3-3
was increased by treatment with OA. Despite OA treatment, ectopic
expression of SelW(U13C) signiﬁcantly inhibited binding of TAZ to
Fig. 4. Nuclear translocation of TAZ is promoted by SelW. (A) C2C12 cells were co-transfected with Flag-TAZ, HA-14-3-3β or His-SelW(U13C) The cells were harvested 24 h after trans-
fection, immunoprecipitated with anti-Flag antibody, and immunoblotted using the indicated antibodies. (B) C2C12 cells were transfected with empty vector or His-SelW(U13C). Cyto-
plasmic and nuclear fractions were obtained at the indicated time points after transfection and immunoblotted using the TAZ antibody. Samples were probed for α-tubulin as a
cytoplasmic marker and lamin B1 as a nuclear marker, and analyzed by western blot using the indicated antibodies (left). The quantity of nuclear TAZ represents the average values at
the indicated time points. The graph indicates the results from three independent experiments (***p b 0.001). Error bars represent ± standard deviation (s.d.), and the p value compares
the vector to His(U13C) (right). (C) C2C12 cells were treated without or with 10, 50 and 100 ng/ml of okadaic acid (OA). After a 6 h treatment, the cells were harvested and analyzed by
western blot using the indicated antibodies. (D) C2C12 cells were co-transfected with His-SelW(U13C), Flag-TAZ, and HA-14-3-3β. At 24 h after transfection, the cells were treated with
50 ng/ml ofOA for 6 h. The cellswere immunoprecipitatedwith anti-Flag antibody, and immunoblottedusing the indicated antibodies. (E) C2C12 cellswere transfectedwith empty vector
or His-SelW(U13C), and were incubated with 25 ng/ml of OA for 12 h prior to harvest. The cytoplasmic and nuclear fractions were obtained at D1 and immunoblotted using the TAZ an-
tibody. Samples were probed for α-tubulin as a cytoplasmic marker and lamin B1 as a nuclear marker.
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Collectively, these data suggest that SelW inhibits binding of TAZ to
14-3-3 and promotes translocation of TAZ to the nucleus.3.5. SelW enhances myogenic differentiation by inhibiting TAZ binding
to 14-3-3
We next investigated whether ectopic expression of SelW(U13C)
promotedmyogenic differentiation. As shown in Fig. 5A, ectopic expres-
sion of SelW(U13C) elevated the expression of myogenin but did not
affect the expression of MyoD (Fig. 5A). Furthermore, when TAZ phos-
phorylation was sustained by OA treatment, myogenin expression was
increased by SelW (Fig. 5B). Next, we examinedwhether ectopic expres-
sion of SelW in endogenous SelW-knockdown C2C12 cells could en-
hance myogenic differentiation. We knocked down SelW in C2C12 cells
and then ectopically expressed SelW(U13C). Ectopic expression of
SelW(U13C) restored the expression of myogenin that was decreased
by SelW-speciﬁc siRNA (Fig. 5C). Binding of TAZ to 14-3-3was decreased
by ectopic expression of SelW(U13C) (Fig. 5D). We also found that
binding of TAZ to 14-3-3 was decreased with increasing amounts ofSelW(U13C) (Fig. 5E). These results clearly demonstrate that SelW
enhances myogenic differentiation by inhibiting TAZ binding to 14-3-3.3.6. Binding of TAZ to MyoD is increased by the action of SelW
Most TAZ is translocated to the nucleus during skeletal muscle cell
differentiation to physically interact with MyoD. This promotes MyoD-
inducedmyogenin andMCK expression for skeletal muscle cell differen-
tiation [26]. To investigate TAZ binding toMyoD,we overexpressed Flag-
tagged TAZ and HA-tagged MyoD and observed binding of TAZ to MyoD
(Fig. 6A). Translocation of TAZ to the nucleus was reduced during SelW-
knockdown C2C12 cell differentiation (Fig. 3A), whereas ectopic expres-
sion of SelW(U13C) promoted TAZ translocation to the nucleus (Fig. 4B).
Therefore, we next investigated whether SelW(U13C) regulated the
interaction between TAZ and MyoD. We examined binding of TAZ
to MyoD during ectopic expression of SelW(U13C). The interaction
between TAZ and MyoD was increased by ectopic expression of
SelW(U13C) (Fig. 6B). These results suggest that SelW is essential for
skeletal muscle differentiation by increasing TAZ binding to MyoD.
Fig. 7 is a model of myogenic differentiation regulated by SelW.
Fig. 5. Enforced expression of SelW enhances C2C12 differentiation. (A) C2C12 cells were
transfectedwith empty vector orHis-SelW(U13C). The cellswereharvested atD1 after trans-
fection and were analyzed by western blot using the indicated antibodies. (B) C2C12 cells
were transfected with empty vector or His-SelW(U13C) and treated with 25 ng/ml of OA
for 12 h prior to harvest. The cells were harvested at D1 and analyzed by western blot
using the indicated antibodies. (C) Electroporation of C2C12 cells was performed using a
Neon transfection system according to themanufacturer's instructions for transient transfec-
tion with siSelW. Twelve hours after transfection with siSelW, the cells were co-transfected
withHis-SelW(U13C) using Lipofectamine 2000 transfection reagent. The cellswereharvest-
ed at D1 and analyzed by western blot using the indicated antibodies. (D) Electroporation of
C2C12 cellswas performedusing aNeon transfection systemaccording to themanufacturer's
instructions for transient transfection with siSelW. Twelve hours after transfection with
siSelW, the cells were co-transfected with His-SelW(U13C), Flag-TAZ and HA-14-3-3β
using Lipofectamine 2000 transfection reagent. Twenty-four hours after transfection, the
cells were immunoprecipitated with anti-Flag antibody, and immunoblotted using the
indicated antibodies. (E) HEK293 cells were co-transfected with Flag-TAZ, HA-14-3-3β and
increasing amount of 0, 0.25, 0.5, 1, and 2 μg g His-SelW(U13C). Twenty-four hours after
transfection, the cellswere immunoprecipitatedwith anti-Flag antibody, and immunoblotted
using the indicated antibodies.
Fig. 6. SelW enhances TAZ binding of to MyoD. (A) HEK293 cells were co-transfected with
Flag-TAZ or HA-MyoD, and the cells were harvested 24 h after transfection. Cell extracts
were immunoprecipitated with anti-Flag antibody and immunoblotted using the indicated
antibodies. (B) C2C12 cells were co-transfected with Flag-TAZ, HA-MyoD, or His-
SelW(U13C) and harvested at D1 after transfection. Cell extracts were immunoprecipitated
with anti-Flag antibody and immunoblotted using the indicated antibodies.
Fig. 7. A regulatorymechanism of SelW in skeletal muscle differentiation by inhibiting TAZ
binding to 14-3-3.
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SelW is involved in growth and proliferation of C2C12 skeletal mus-
cle [9]. In this study, we investigated the potential role of SelW to
regulate C2C12 skeletal muscle differentiation. We found that SelW
mRNA expression was up-regulated during C2C12 cell differentiation
(Fig. 1B), whereas down-regulation of SelW signiﬁcantly diminished
C2C12 cell differentiation, which resulted from a reduction in theexpression of myogenin and MyHC but not MyoD (Fig. 1D and E). We
have previously reported that SelW mRNA and protein expression
levels are elevated by the interaction between a speciﬁc E-box of SelW
and MyoD during early skeletal muscle differentiation [12]. MyoD is
essential for skeletal muscle differentiation [36] and plays a key role in
the expression of muscle-speciﬁc genes [37]. Binding of MyoD to target
proteins including TAZ is required for expression of the muscle-speciﬁc
genes myogenin and MCK [26].
Nuclear translocation of TAZ is required for the interaction with
MyoD [26]. Nuclear translocation of TAZ is regulated by LATS, which
phosphorylates TAZ at Ser66, 89, 117, and 311 [27]. In particular, TAZ
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at Ser89 and Ser311 [29]. Phosphorylation at Ser311 mediates
polyubiquitination and degradation of TAZ through interaction with
SCFβ-TrCP E3 ligase [28,29,38]. The Ser89 in TAZ generates a 14-3-3 binding
site [28]. TAZ binding to 14-3-3 is inhibited with increasing amounts of
the serine/threonine inhibitor K252a. A 14-3-3 mutant that disrupts the
E180K phosphopeptide-binding pocket and K49E eliminates TAZ binding.
Thus, phosphorylation of TAZ by a serine/threonine kinase is required for
its interactionwith 14-3-3 [17,30,39–41]. AKT is another serine/threonine
kinase involved in various cellular processes [42,43]. AKT is known to
phosphorylate YAP which shares 50% sequence with TAZ [27,44]. We
have reported that SelW enhances activity of the mTORC2/AKT pathway
for AKT phosphorylation at Ser473 by inhibiting 14-3-3 binding to Rictor
[14]. This raises the question ofwhether TAZ phosphorylation is increased
due to AKT activity during C2C12 muscle differentiation. However, phos-
phorylation of TAZ at Ser89 is regulated by LATS not AKT [45]. Replacing
Ser89 with Ala (S89A) in TAZ completely abolishes the interaction with
14-3-3, and nuclear translocation of the mutant TAZ is more than that
of the wild-type protein [25,27,30].
The increased binding of TAZ at Ser89 to 14-3-3 reduces nuclear
translocation and transcriptional activity of TAZ [28]. Binding of TAZ to
14-3-3 decreased during C2C12 cell differentiation, which resulted in
translocation of TAZ to the nucleus (Fig. 2). Nuclear translocation
of TAZ is required for skeletal muscle differentiation and interaction
with MyoD. The transcription activity of the MyoD-mediated genes
myogenin and MCK is promoted by the interaction with TAZ, and
myogenin expression is increased by inducing the expression of TAZ
in regenerating muscle after injury. The interaction between MyoD
and a promoter of myogenin was attenuated upon down-regulation of
TAZ,which resulted in diminishedmyogenic differentiation. In addition,
the WW domain of TAZ (aa 1–163) is required for interaction with the
C-terminal (aa 162–318) of MyoD [26].
We have reported that SelW regulates binding of 14-3-3 to its target
proteins, CDC25B and Rictor, to enhance cell growth [13,14]. Binding
of 14-3-3 to CDC25B and Rictor is increased signiﬁcantly in SelW-
knockdown cells, and ectopic expression of SelW reduces these interac-
tions [13,14]. As shown in Fig. 3A, SelW-knockdown cells reduced trans-
location of TAZ to the nucleus compared to that of control cells (Fig. 3A)
because down-regulation of SelW increased TAZ binding to 14-3-3
(Fig. 3C). The observation that down-regulation of SelW increased TAZ
binding to 14-3-3 is very intriguing. Although SelW did not interact
with TAZ (Fig. 3B), it is possible that SelW may be a TAZ regulatory
molecule during C2C12 cell differentiation.
PP1 is a serine/threoninephosphatase involved in various cellular pro-
cesses [46]. Phosphorylation of TAZ at Ser89 is decreased by PP1. The ec-
topic expressionof PP1 signiﬁcantly reduced thebindingof TAZ to 14-3-3,
which resulted in an increase in the translocation of TAZ to the nucleus.
PP1 expression is reduced byOAwith an IC50 of 20 nM [33,35]. Phosphor-
ylation of TAZ at Ser89 and its interaction with 14-3-3 was increased
signiﬁcantly following treatmentwith OA (Fig. 4C andD). Ectopic expres-
sion of SelW decreased the binding of TAZ to 14-3-3 that was increased
by treatment with OA (Fig. 4A and D). Furthermore, translocation of
TAZ to the nucleus was increased by SelW (Fig. 4B and E). Therefore,
our ﬁndings suggest that SelW inhibits TAZ binding to 14-3-3 and
promotes nuclear localization of TAZ.
In addition to our recent ﬁndings [13,14], increasing amounts of SelW
decreased the binding of 14-3-3 to its target protein TAZ (Fig. 5C). 14-3-3
plays widespread roles in various signaling processes such as cell growth
and development through its interactionwith signaling pathway proteins
[17,18]. Therefore, SelW may be involved in regulating the association
between 14-3-3 andmany other target proteins. The general mechanism
of regulation of this association remains to be elucidated. 14-3-3 recog-
nizes the RSXSXP phosphor-serine motif and the RXXXSXP phosphor-
threonine motif of target proteins [41,47]. TAZ contains four HXRXXS
phosphorylation motifs [27,30,33]. However, SelW does not contain
the phosphorylation motifs found in its well-known partners. 14-3-3binds not only to the phosphorylation motif but also to the non-
phosphorylation motif of binding partners [17,30,47,48]. SelW may
interact with 14-3-3 in a redox manner [5,15,16]. The cysteine in 14-
3-3 (Cys191 and Cys195 in 14-3-3 β and γ) has been identiﬁed as a
SelW binding site, and residues in SelW (aa 8–22, 38–51 and 58–64)
were predicted to be 14-3-3 binding regions in an NMR study [16].
Further study with a mutant SelW that disrupts the interaction with
14-3-3 remains.
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